GenoSpace Expands Board With Appointment Of Michelle Munson

CAMBRIDGE, Mass., Jan. 22, 2015 /PRNewswire/ -- GenoSpace, a precision medicine software company that has developed a comprehensive suite of tools to enable the broad use of genomic, imaging and other biomedical data in research and clinical care, today announced the appointment of Michelle Munson, CEO of Aspera, an IBM Company, to its board as an independent director.

Logo -

"We are pleased to welcome Michelle to the leadership team at GenoSpace," said John Quackenbush, Chairman of the Board of GenoSpace. "We have had a strong relationship with Michelle's team at Aspera beginning with some of our earliest customer deployments, and we welcome her depth of experience and clear enthusiasm for applying advanced technical solutions to solving complex problems."

"GenoSpace is a highly talented and promising team that is focused on fundamentally advancing medicine through innovation at the intersection of genomic science and computing, an area in which I have had significant exposure through Aspera, and which means a great deal to me as a computer scientist. I am honored to help contribute my experience in creating and growing a technology start-up to this exceptional group," said Munson.

Ms. Munson is Chief Executive Officer and co-founder of Aspera, which was acquired by IBM in January 2014. She is co-inventor, along with Serban Simu, of Aspera's Emmy Awardwinning FASP transport technology for high-performance bulk data transfer. Before she founded Aspera in 2004, Ms. Munson was a software engineer at research and start-up companies specializing in content networking and distributed systems. She holds dual B.Sc. degrees in electrical engineering and physics from Kansas State University and was a Goldwater Scholar for achievement in science and mathematics, as well as a Fulbright Scholar at Cambridge University, where she received a postgraduate diploma in computer science. In 2006, Ms. Munson became the youngest-ever KSU College of Engineering Alumni Fellow.

About GenoSpace
At GenoSpace, we are Digital Architects of Genomic Medicine. GenoSpace has built a comprehensive platform for precision medicine to enable interpretation, analysis, reporting and collaboration on high-dimensional genomic and other biomedical data. With specific applications supporting research, development, pathology and clinical care, many of the most advanced precision medicine organizations are powered by GenoSpace. Please visit www.genospace.comfor more information.

Daniel Meyer
[email protected]

To view the original version on PR Newswire, visit:

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.